Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Vandana Singh

March 25, 2025

Benzinga

Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target.

Latest Ratings for AVTX

Date	Firm	Action	From	To
Mar 2022	Jefferies	Downgrades	Buy	Hold
Mar 2022	RBC Capital	Maintains		Outperform
Sep 2021	RBC Capital	Initiates Coverage On		Outperform

View More Analyst Ratings for AVTX

View the Latest Analyst Ratings

Market Impact

High Mortgage Rates, Economic Uncertainty Rain On Spring Home-Buying Season

April 25, 2025

Benzinga

Market Impact

Here's How Much $1000 Invested In Starbucks 15 Years Ago Would Be Worth Today

April 25, 2025

Benzinga

Market Impact

Marijuana Stock Movers For April 25, 2025

April 25, 2025

Benzinga

Market Impact

High Mortgage Rates, Economic Uncertainty Rain On Spring Home-Buying Season

April 25, 2025

Benzinga

Market Impact

Here's How Much $1000 Invested In Starbucks 15 Years Ago Would Be Worth Today

April 25, 2025

Benzinga

Market Impact

Marijuana Stock Movers For April 25, 2025

April 25, 2025

Benzinga

Markets

Delicate Balance Between Growth, Inflation: Lynam

March 21, 2025

Bloomberg

Market Impact

Expert Outlook: Dycom Industries Through The Eyes Of 4 Analysts

March 19, 2025

Benzinga

Business & Finance

OpenAI and start-ups race to generate code and transform software industry

April 18, 2025

Financial Times

Enjoy premium content in your inbox.

You're in! Check your email to learn more.

Oops! Something went wrong while submitting the form.

Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

Latest Ratings for AVTX

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

News

Tools

More

Follow